8-K 1 f8k050718_wizepharmainc.htm CURRENT REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported) May 7, 2018

Wize Pharma, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware |  | 000-52545 |  | 88-0445167
(State or Other Jurisdiction of Incorporation) |  | (Commission File Number) |  | (IRS Employer Identification No.)

24 Hanagar Street, Hod Hasharon, Israel |  | 4527708
(Address of Principal Executive Offices) |  | (Zip Code)

Registrant’s telephone number, including area code: +(972) 72-260-0536

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

| ☐ | Written communications pursuant to Rule 425 under the Securities Act
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 7.01. | Regulation FD Disclosure.

On May 7, 2018, Wize Pharma, Inc. (the “Company”) posted an updated corporate presentation and an investor fact sheet on the Company’s website at www.wizepharma.com, copies of which are furnished as Exhibit 99.1and 99.2 hereto, pursuant to Item 7.01 of Form 8-K.

In accordance with General Instruction B.2 of Form 8-K, the information furnished pursuant to this Item 7.01, and including Exhibit 99.1 furnished herewith, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

The Securities and Exchange Commission encourages registrants to disclose forward-looking information so that investors can better understand the future prospects of a registrant and make informed investment decisions. This Current Report on Form 8-K and exhibits may contain these types of statements, which are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and which involve risks, uncertainties and reflect the Registrant’s judgment as of the date of this Current Report on Form 8-K. Forward-looking statements may relate to, among other things, operating results and are indicated by words or phrases such as “expects,” “should,” “will,” and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this Current Report on Form 8-K. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented within.

Item 8.01 | Other Events

On May 7, 2018, the Company issued a press release announcing that it will present at the 3rd Annual Disruptive Growth & Healthcare Conference hosted by RHK Capital and Reed Smith on Tuesday, May 8, 2018 at 12:00 pm EDT. The Company’s COO, Noam Danenberg, will deliver the presentation in Room A/B and meet with investors during a follow-on Q&A session immediately following the presentation in Room 10. A copy of the press release is attached as Exhibit 99.3 hereto and incorporated herein by reference.

Item 9.01. | Financial Statement and Exhibits.

(d) | Exhibits.

Exhibit Number |  | Description
99.1 |  | Corporate Presentation
99.2 |  | Investor Fact Sheet
99.3 |  | Press Release dated May 7, 2018

| 1 |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| Wize Pharma, Inc.
Date: May 7, 2018 | By: | /s/ Or Eisenberg
|  | Name: | Or Eisenberg
|  | Title: | Acting Chief Executive Officer, Chief Financial Officer, Treasurer and Secretary

| 2 |